The abstract is read at the publisher; the summary is JClub's.
In CALR-mutant myeloproliferative neoplasms, NK cells show preserved degranulation and high TIGIT expression, with TIGIT blockade reducing platelet numbers in a transplant mouse model.
- Why it matters: MPNs feature impaired NK-cell activity, and CALR mutations are a key immunotherapy target, but the checkpoint mechanisms limiting NK function in CALR-mutant disease are unclear.
- What they did: The study compared NK-cell maturation and degranulation in a CALR-mutant mouse model and in MPN patients, then assessed TIGIT and CD112 expression and tested TIGIT blockade in a transplant mouse model.
- The result: CALR-mutant NK cells degranulate normally and express high TIGIT, unlike JAK2-mutant counterparts; CD34+ patient cells show elevated CD112, and TIGIT blockade reduces platelet numbers, supporting checkpoint-targeted restoration of NK immunity in CALR-mutant MPNs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.